MYISR
tradurre in italiano

Why the Italian Sunshine Act Is More Operationally Complex Than US Open Payments

by | Jun 11, 2026 | en

Table of content

Author



Ned Mumtaz
Director
Vector Health Compliance

 

Ned Mumtaz is an international transparency reporting expert with extensive experience producing accurate and compliant transparency reports for over 150 pharmaceutical companies globally.
He has held leadership positions at Pfizer and Otsuka, distinguishing himself by ensuring high standards of accuracy, reliability, and regulatory compliance in reporting processes. He is recognized in the industry for his contributions to the development of global transparency models and for promoting operational best practices in compliance.

Recent Blogs

Cerchi supporto per la compliance al Sunshine Act?

Scopri i nostri Partner consigliati — soluzioni legali, tecnologiche e operative selezionate per accompagnarti nella rendicontazione della trasparenza.

Hai domande pratiche?

Dai un’occhiata alla nostra sezione Domande Frequenti per risposte chiare su scadenze, obblighi e strategie.

Italy’s Sunshine Act, officially known as Law No. 62/2022, does not simply mirror its American counterpart. In several important respects, it introduces broader and more operationally demanding requirements.

For pharmaceutical, medical device, and life sciences companies operating in or engaging with the Italian market, the preparation window remains strategically important.

Italy’s Life Sciences Market Demands Attention

The stakes are significant. According to the Chambers Life Sciences 2026 Italy guide, market data analysts estimate that the Italian pharmaceutical market reached approximately USD 60 billion in revenues in 2024 and could exceed USD 80 billion by 2030. The same guide describes Italy as the world’s sixth-largest exporter of medicines and the third-largest exporter of packaged drugs after Germany and Switzerland.

This is not a peripheral market. Italy is one of Europe’s most important life sciences markets, with a strong pharmaceutical manufacturing base, significant export activity, and an active healthcare and clinical research environment. With the introduction of the Italian Sunshine Act, companies operating in this market face one of Europe’s most ambitious healthcare transparency frameworks.

Broader Covered Entities, Including Sectors the US Does Not Touch

Under the US Open Payments program, covered reporting entities are relatively well defined: manufacturers of covered drugs, biologicals, devices, and medical supplies, as well as certain group purchasing organizations.

The Italian Sunshine Act casts a wider net. It applies to producing companies that directly or indirectly, including through intermediaries, carry out activities related to the production or marketing of medicines, medical devices, equipment, goods, or services in the field of human or animal health.

This scope may include companies beyond traditional pharmaceutical and medical device manufacturers, depending on their activities and relationship to the Italian healthcare ecosystem. Animal health companies, nutraceutical producers, cosmetics manufacturers, and companies involved in organising medical conferences or congresses may need to assess carefully whether their activities fall within scope.

In short, companies operating in or supplying the Italian healthcare and life sciences ecosystem should not assume that US Open Payments logic will be enough.

A Broader Pool of Covered Recipients

In the US, covered recipients include physicians, certain advanced practice providers or non-physician practitioners, and teaching hospitals.

Italy takes a broader approach. The Italian framework covers healthcare-sector professionals and healthcare organisations, including a wider range of individuals and entities involved in healthcare activity, decision-making, administration, research, education, and institutional relationships.

This may include professionals, organisations, patient associations, scientific societies, research institutions, and other entities that participate in the healthcare ecosystem, depending on the nature of the transfer or relationship.

The Italian framework reflects a broader view of healthcare-sector influence and should be assessed across both individual professionals and healthcare organisations.

Thresholds and Reporting Timing

The Italian Sunshine Act sets clear thresholds for transfers of value. For HCPs, individual transfers exceeding €100 or annual totals exceeding €1,000 are reportable. For HCOs, individual transfers exceeding €1,000 or annual totals exceeding €2,500 are in scope.

The law also covers certain agreements, participation in conferences or training events, advisory and scientific bodies, consultancy, teaching and research relationships, ownership interests, and payments connected to intellectual or industrial property rights.

The precise operational timeline depends on the formal activation of the Sanità Trasparente register and related implementation steps. Companies should avoid waiting for the final go-live notice before beginning data mapping and readiness work.

The Intermediary Question: Italy’s Operational Complication

Another operationally complex feature of the Italian framework is the treatment of intermediaries and the need to capture information about parties involved in arranging, facilitating, or supporting relevant transfers or relationships.

This is not a concept that maps neatly onto US Open Payments reporting. For companies with cross-border activity, global clinical studies, headquarters-led engagements, or third-party-managed events, intermediary-related information can fundamentally change the data collection process.

Companies need to understand not only who received the transfer of value, but also how the interaction was arranged, who facilitated it, and where that information is captured internally.

Penalties That Make Accuracy Essential

The Italian Sunshine Act establishes financial penalties for non-compliance. Failure to report can result in a base fine of €1,000 plus twenty times the value of each unreported transfer. False reporting can trigger fines ranging from €5,000 to €100,000.

These penalties matter, but financial exposure is only part of the risk. Once the Sanità Trasparente register is operational, reported data will be publicly accessible, meaning errors or omissions may also create reputational exposure with HCPs, HCOs, patients, journalists, competitors, and regulators.

What Companies Must Do Now

Companies should not treat Italian Sunshine reporting as a simple extension of their US Open Payments program. Instead, they should conduct a structured gap analysis across relevant source systems, including expense management platforms, ERP systems, contract lifecycle management tools, event management systems, clinical research systems, and third-party agency data.

Key questions include:

  • Are reportable transfers of value being identified consistently?
  • Are HCP and HCO records complete and reliable?
  • Are Italian-specific identifiers and data fields being captured?
  • Are intermediary-related details being recorded where relevant?
  • Are third-party agencies collecting the data needed for reporting?
  • Are departments using consistent definitions and field names?
  • Can the data be transformed into the required XML format when needed?

The path forward requires intentional setup: mapping reportable transfers of value across departments, building or sourcing reliable Italian HCP and HCO master data, training employees on what must be captured at the point of interaction, and establishing a reporting mechanism aligned with the Sanità Trasparente submission framework.

Italy is not a market where legacy compliance playbooks can be copied without adaptation. The combination of a major life sciences market, a broad transparency framework, and complex operational data requirements makes Italian Sunshine reporting one of the more demanding transparency challenges facing global healthcare companies.

Companies that begin setup now will be better positioned to report with confidence. Those that wait may find themselves chasing data gaps, classification issues, and source-system errors against a live deadline.

Table of content

Italy’s Sunshine Act, officially known as Law No. 62/2022, does not simply mirror its American counterpart. In several important respects, it introduces broader and more operationally demanding requirements.

For pharmaceutical, medical device, and life sciences companies operating in or engaging with the Italian market, the preparation window remains strategically important.

Italy’s Life Sciences Market Demands Attention

The stakes are significant. According to the Chambers Life Sciences 2026 Italy guide, market data analysts estimate that the Italian pharmaceutical market reached approximately USD 60 billion in revenues in 2024 and could exceed USD 80 billion by 2030. The same guide describes Italy as the world’s sixth-largest exporter of medicines and the third-largest exporter of packaged drugs after Germany and Switzerland.

This is not a peripheral market. Italy is one of Europe’s most important life sciences markets, with a strong pharmaceutical manufacturing base, significant export activity, and an active healthcare and clinical research environment. With the introduction of the Italian Sunshine Act, companies operating in this market face one of Europe’s most ambitious healthcare transparency frameworks.

Broader Covered Entities, Including Sectors the US Does Not Touch

Under the US Open Payments program, covered reporting entities are relatively well defined: manufacturers of covered drugs, biologicals, devices, and medical supplies, as well as certain group purchasing organizations.

The Italian Sunshine Act casts a wider net. It applies to producing companies that directly or indirectly, including through intermediaries, carry out activities related to the production or marketing of medicines, medical devices, equipment, goods, or services in the field of human or animal health.

This scope may include companies beyond traditional pharmaceutical and medical device manufacturers, depending on their activities and relationship to the Italian healthcare ecosystem. Animal health companies, nutraceutical producers, cosmetics manufacturers, and companies involved in organising medical conferences or congresses may need to assess carefully whether their activities fall within scope.

In short, companies operating in or supplying the Italian healthcare and life sciences ecosystem should not assume that US Open Payments logic will be enough.

A Broader Pool of Covered Recipients

In the US, covered recipients include physicians, certain advanced practice providers or non-physician practitioners, and teaching hospitals.

Italy takes a broader approach. The Italian framework covers healthcare-sector professionals and healthcare organisations, including a wider range of individuals and entities involved in healthcare activity, decision-making, administration, research, education, and institutional relationships.

This may include professionals, organisations, patient associations, scientific societies, research institutions, and other entities that participate in the healthcare ecosystem, depending on the nature of the transfer or relationship.

The Italian framework reflects a broader view of healthcare-sector influence and should be assessed across both individual professionals and healthcare organisations.

Thresholds and Reporting Timing

The Italian Sunshine Act sets clear thresholds for transfers of value. For HCPs, individual transfers exceeding €100 or annual totals exceeding €1,000 are reportable. For HCOs, individual transfers exceeding €1,000 or annual totals exceeding €2,500 are in scope.

The law also covers certain agreements, participation in conferences or training events, advisory and scientific bodies, consultancy, teaching and research relationships, ownership interests, and payments connected to intellectual or industrial property rights.

The precise operational timeline depends on the formal activation of the Sanità Trasparente register and related implementation steps. Companies should avoid waiting for the final go-live notice before beginning data mapping and readiness work.

The Intermediary Question: Italy’s Operational Complication

Another operationally complex feature of the Italian framework is the treatment of intermediaries and the need to capture information about parties involved in arranging, facilitating, or supporting relevant transfers or relationships.

This is not a concept that maps neatly onto US Open Payments reporting. For companies with cross-border activity, global clinical studies, headquarters-led engagements, or third-party-managed events, intermediary-related information can fundamentally change the data collection process.

Companies need to understand not only who received the transfer of value, but also how the interaction was arranged, who facilitated it, and where that information is captured internally.

Penalties That Make Accuracy Essential

The Italian Sunshine Act establishes financial penalties for non-compliance. Failure to report can result in a base fine of €1,000 plus twenty times the value of each unreported transfer. False reporting can trigger fines ranging from €5,000 to €100,000.

These penalties matter, but financial exposure is only part of the risk. Once the Sanità Trasparente register is operational, reported data will be publicly accessible, meaning errors or omissions may also create reputational exposure with HCPs, HCOs, patients, journalists, competitors, and regulators.

What Companies Must Do Now

Companies should not treat Italian Sunshine reporting as a simple extension of their US Open Payments program. Instead, they should conduct a structured gap analysis across relevant source systems, including expense management platforms, ERP systems, contract lifecycle management tools, event management systems, clinical research systems, and third-party agency data.

Key questions include:

  • Are reportable transfers of value being identified consistently?
  • Are HCP and HCO records complete and reliable?
  • Are Italian-specific identifiers and data fields being captured?
  • Are intermediary-related details being recorded where relevant?
  • Are third-party agencies collecting the data needed for reporting?
  • Are departments using consistent definitions and field names?
  • Can the data be transformed into the required XML format when needed?

The path forward requires intentional setup: mapping reportable transfers of value across departments, building or sourcing reliable Italian HCP and HCO master data, training employees on what must be captured at the point of interaction, and establishing a reporting mechanism aligned with the Sanità Trasparente submission framework.

Italy is not a market where legacy compliance playbooks can be copied without adaptation. The combination of a major life sciences market, a broad transparency framework, and complex operational data requirements makes Italian Sunshine reporting one of the more demanding transparency challenges facing global healthcare companies.

Companies that begin setup now will be better positioned to report with confidence. Those that wait may find themselves chasing data gaps, classification issues, and source-system errors against a live deadline.

Author



Ned Mumtaz
Director
Vector Health Compliance

 

Ned Mumtaz is an international transparency reporting expert with extensive experience producing accurate and compliant transparency reports for over 150 pharmaceutical companies globally.
He has held leadership positions at Pfizer and Otsuka, distinguishing himself by ensuring high standards of accuracy, reliability, and regulatory compliance in reporting processes. He is recognized in the industry for his contributions to the development of global transparency models and for promoting operational best practices in compliance.

Recent Blogs

Cerchi supporto per la compliance al Sunshine Act?

Scopri i nostri Partner consigliati — soluzioni legali, tecnologiche e operative selezionate per accompagnarti nella rendicontazione della trasparenza.

Hai domande pratiche?

Dai un’occhiata alla nostra sezione Domande Frequenti per risposte chiare su scadenze, obblighi e strategie.